Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gordon Moss

Internal Medicine Farmington Hills, MI Medical Doctor

NPI 1639154925 CMS profile 345956

30840 Northwestern Hwy, Suite 300, Farmington Hills, MI 48334

Open in the dashboard

General payments

$4,808

274 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gordon Moss of Farmington Hills, MI is reported in the CMS Open Payments database as having received $4,808 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,045 40
2024 General $619 37
2023 General $679 38
2022 General $768 40
2021 General $625 39
2020 General $124 9
2019 General $949 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gordon Moss
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gordon Moss were reported at $1,045. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gordon Moss Internal Medicine median Middle half National median
2019 $949 $159 $48–$570 $163
2020 $124 $119 $33–$402 $114
2021 $625 $135 $37–$521 $132
2022 $768 $141 $42–$496 $149
2023 $679 $149 $45–$519 $160
2024 $619 $154 $47–$537 $164
2025 $1,045 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $913 39 payments
  2. Novo Nordisk Inc $566 32 payments
  3. Lilly USA, LLC $444 29 payments
  4. AbbVie, Inc. $403 17 payments
  5. Pfizer Inc. $387 33 payments
  6. GlaxoSmithKline, LLC. $312 21 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $293 11 payments
  8. Novartis Pharmaceuticals Corporation $291 18 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $171 8 payments
  10. Merck Sharp & Dohme Corporation $164 16 payments
  11. Other $864 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,808 274 payments
Products named General payments · program years 2019–2025
  1. Ozempic $493 28 payments
  2. RYBELSUS $428 24 payments
  3. UBRELVY $390 16 payments
  4. Prolia $327 16 payments
  5. Repatha Cardiology $300 18 payments
  6. REPATHA Cardiovascular $286 5 payments
  7. MOUNJARO $276 17 payments
  8. EVENITY $234 15 payments
  9. TRELEGY ELLIPTA $200 14 payments
  10. QULIPTA $179 4 payments
  11. Other $4,172 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

5,871

Median for Internal Medicine: 777

Drug cost

$910,496

Median for Internal Medicine: $73,373

Branded share of claims

23.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 113 $169,006
Eliquis Apixaban Brand 114 $155,179
Mounjaro Tirzepatide Brand 98 $143,153
Trulicity Dulaglutide Brand 61 $103,806
Repatha Sureclick Evolocumab Brand 44 $64,378
Xarelto Rivaroxaban Brand 55 $42,319
Ozempic Semaglutide Brand 27 $40,211
Januvia Sitagliptin Phosphate Brand 31 $36,324
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $34,959
Farxiga Dapagliflozin Propanediol Brand 16 $18,624

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$91,117

Of which drugs: $786

Medicare patients

202

Average age 77

Services billed

1,316

83 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 42%
Ischemic heart disease 41%
Atrial fibrillation 22%
Chronic kidney disease 22%
Cancer 21%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $70
$70 98 —
Repatha
  • Amgen Inc. $53
$53 44 —
NEXLETOL
  • Esperion Therapeutics, Inc. $52
$52 — —
RYBELSUS
  • Novo Nordisk Inc $46
$46 — —
Ozempic
  • Novo Nordisk Inc $46
$46 27 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record